nodes	percent_of_prediction	percent_of_DWPC	metapath
Betaxolol—CYP2D6—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00458	0.0843	CbGpPWpGaD
Betaxolol—CYP2D6—Miscellaneous substrates—CYP4B1—urinary bladder cancer	0.00298	0.0548	CbGpPWpGaD
Betaxolol—CYP1A2—Arylamine metabolism—NAT2—urinary bladder cancer	0.00293	0.0538	CbGpPWpGaD
Betaxolol—CYP2D6—Fatty acids—CYP4B1—urinary bladder cancer	0.0025	0.0459	CbGpPWpGaD
Betaxolol—CYP2D6—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00212	0.0389	CbGpPWpGaD
Betaxolol—CYP1A2—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00203	0.0373	CbGpPWpGaD
Betaxolol—CYP1A2—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00179	0.033	CbGpPWpGaD
Betaxolol—CYP2D6—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00172	0.0316	CbGpPWpGaD
Betaxolol—CYP1A2—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00146	0.0268	CbGpPWpGaD
Betaxolol—CYP1A2—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00128	0.0235	CbGpPWpGaD
Betaxolol—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.0011	0.0202	CbGpPWpGaD
Betaxolol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000824	0.0151	CbGpPWpGaD
Betaxolol—CYP2D6—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000813	0.0149	CbGpPWpGaD
Betaxolol—CYP1A2—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.000807	0.0148	CbGpPWpGaD
Betaxolol—CYP1A2—Estrogen metabolism—NQO1—urinary bladder cancer	0.000784	0.0144	CbGpPWpGaD
Betaxolol—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000698	0.0128	CbGpPWpGaD
Betaxolol—CYP1A2—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000689	0.0127	CbGpPWpGaD
Betaxolol—CYP2D6—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000668	0.0123	CbGpPWpGaD
Betaxolol—CYP1A2—Phase II conjugation—GSTZ1—urinary bladder cancer	0.000658	0.0121	CbGpPWpGaD
Betaxolol—Weight increased—Doxorubicin—urinary bladder cancer	0.000634	0.000671	CcSEcCtD
Betaxolol—Epistaxis—Epirubicin—urinary bladder cancer	0.000633	0.00067	CcSEcCtD
Betaxolol—Pruritus—Gemcitabine—urinary bladder cancer	0.000633	0.000669	CcSEcCtD
Betaxolol—Nausea—Thiotepa—urinary bladder cancer	0.000632	0.000668	CcSEcCtD
Betaxolol—Weight decreased—Doxorubicin—urinary bladder cancer	0.00063	0.000667	CcSEcCtD
Betaxolol—Sinusitis—Epirubicin—urinary bladder cancer	0.00063	0.000666	CcSEcCtD
Betaxolol—Feeling abnormal—Etoposide—urinary bladder cancer	0.00063	0.000666	CcSEcCtD
Betaxolol—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000629	0.000665	CcSEcCtD
Betaxolol—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000627	0.000663	CcSEcCtD
Betaxolol—Pneumonia—Doxorubicin—urinary bladder cancer	0.000625	0.000661	CcSEcCtD
Betaxolol—CYP1A2—Phase II conjugation—GSTO2—urinary bladder cancer	0.000624	0.0115	CbGpPWpGaD
Betaxolol—CYP1A2—Phase II conjugation—NAT1—urinary bladder cancer	0.000624	0.0115	CbGpPWpGaD
Betaxolol—Pruritus—Fluorouracil—urinary bladder cancer	0.000622	0.000658	CcSEcCtD
Betaxolol—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000621	0.000657	CcSEcCtD
Betaxolol—Infestation—Doxorubicin—urinary bladder cancer	0.000621	0.000657	CcSEcCtD
Betaxolol—Visual impairment—Methotrexate—urinary bladder cancer	0.000621	0.000656	CcSEcCtD
Betaxolol—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000614	0.00065	CcSEcCtD
Betaxolol—Bradycardia—Epirubicin—urinary bladder cancer	0.000614	0.000649	CcSEcCtD
Betaxolol—CYP1A2—Estrogen Receptor Pathway—ESR1—urinary bladder cancer	0.000612	0.0112	CbGpPWpGaD
Betaxolol—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000612	0.000647	CcSEcCtD
Betaxolol—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000609	0.000644	CcSEcCtD
Betaxolol—Urticaria—Etoposide—urinary bladder cancer	0.000607	0.000642	CcSEcCtD
Betaxolol—Stomatitis—Doxorubicin—urinary bladder cancer	0.000606	0.00064	CcSEcCtD
Betaxolol—Rhinitis—Epirubicin—urinary bladder cancer	0.000604	0.000639	CcSEcCtD
Betaxolol—Body temperature increased—Etoposide—urinary bladder cancer	0.000604	0.000639	CcSEcCtD
Betaxolol—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000604	0.000639	CcSEcCtD
Betaxolol—Eye disorder—Methotrexate—urinary bladder cancer	0.000602	0.000637	CcSEcCtD
Betaxolol—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000602	0.000637	CcSEcCtD
Betaxolol—CYP1A2—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000601	0.011	CbGpPWpGaD
Betaxolol—Tinnitus—Methotrexate—urinary bladder cancer	0.000601	0.000635	CcSEcCtD
Betaxolol—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.0006	0.000634	CcSEcCtD
Betaxolol—Asthenia—Cisplatin—urinary bladder cancer	0.000598	0.000633	CcSEcCtD
Betaxolol—Pharyngitis—Epirubicin—urinary bladder cancer	0.000598	0.000633	CcSEcCtD
Betaxolol—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000598	0.000632	CcSEcCtD
Betaxolol—Sweating—Doxorubicin—urinary bladder cancer	0.000596	0.00063	CcSEcCtD
Betaxolol—Epistaxis—Doxorubicin—urinary bladder cancer	0.000586	0.00062	CcSEcCtD
Betaxolol—Angiopathy—Methotrexate—urinary bladder cancer	0.000584	0.000618	CcSEcCtD
Betaxolol—Sinusitis—Doxorubicin—urinary bladder cancer	0.000583	0.000616	CcSEcCtD
Betaxolol—Immune system disorder—Methotrexate—urinary bladder cancer	0.000582	0.000615	CcSEcCtD
Betaxolol—Dizziness—Fluorouracil—urinary bladder cancer	0.000582	0.000615	CcSEcCtD
Betaxolol—Visual impairment—Epirubicin—urinary bladder cancer	0.000581	0.000614	CcSEcCtD
Betaxolol—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.00058	0.000614	CcSEcCtD
Betaxolol—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.00058	0.000613	CcSEcCtD
Betaxolol—Chills—Methotrexate—urinary bladder cancer	0.000578	0.000611	CcSEcCtD
Betaxolol—Diarrhoea—Cisplatin—urinary bladder cancer	0.000571	0.000603	CcSEcCtD
Betaxolol—CYP1A2—Phase II conjugation—UGT2B7—urinary bladder cancer	0.00057	0.0105	CbGpPWpGaD
Betaxolol—Alopecia—Methotrexate—urinary bladder cancer	0.000569	0.000602	CcSEcCtD
Betaxolol—Vomiting—Gemcitabine—urinary bladder cancer	0.000569	0.000602	CcSEcCtD
Betaxolol—Bradycardia—Doxorubicin—urinary bladder cancer	0.000568	0.0006	CcSEcCtD
Betaxolol—CYP1A2—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000566	0.0104	CbGpPWpGaD
Betaxolol—Mental disorder—Methotrexate—urinary bladder cancer	0.000564	0.000597	CcSEcCtD
Betaxolol—Rash—Gemcitabine—urinary bladder cancer	0.000564	0.000597	CcSEcCtD
Betaxolol—Dermatitis—Gemcitabine—urinary bladder cancer	0.000564	0.000596	CcSEcCtD
Betaxolol—Eye disorder—Epirubicin—urinary bladder cancer	0.000563	0.000596	CcSEcCtD
Betaxolol—Hypersensitivity—Etoposide—urinary bladder cancer	0.000563	0.000595	CcSEcCtD
Betaxolol—Tinnitus—Epirubicin—urinary bladder cancer	0.000562	0.000594	CcSEcCtD
Betaxolol—Malnutrition—Methotrexate—urinary bladder cancer	0.000561	0.000593	CcSEcCtD
Betaxolol—Erythema—Methotrexate—urinary bladder cancer	0.000561	0.000593	CcSEcCtD
Betaxolol—Headache—Gemcitabine—urinary bladder cancer	0.00056	0.000593	CcSEcCtD
Betaxolol—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000559	0.000592	CcSEcCtD
Betaxolol—Flushing—Epirubicin—urinary bladder cancer	0.000559	0.000592	CcSEcCtD
Betaxolol—Vomiting—Fluorouracil—urinary bladder cancer	0.000559	0.000591	CcSEcCtD
Betaxolol—Rhinitis—Doxorubicin—urinary bladder cancer	0.000559	0.000591	CcSEcCtD
Betaxolol—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000555	0.000587	CcSEcCtD
Betaxolol—Rash—Fluorouracil—urinary bladder cancer	0.000555	0.000587	CcSEcCtD
Betaxolol—Dermatitis—Fluorouracil—urinary bladder cancer	0.000554	0.000586	CcSEcCtD
Betaxolol—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000554	0.000585	CcSEcCtD
Betaxolol—Headache—Fluorouracil—urinary bladder cancer	0.000551	0.000583	CcSEcCtD
Betaxolol—Dysgeusia—Methotrexate—urinary bladder cancer	0.000549	0.000581	CcSEcCtD
Betaxolol—Asthenia—Etoposide—urinary bladder cancer	0.000548	0.00058	CcSEcCtD
Betaxolol—Angiopathy—Epirubicin—urinary bladder cancer	0.000547	0.000578	CcSEcCtD
Betaxolol—Immune system disorder—Epirubicin—urinary bladder cancer	0.000544	0.000576	CcSEcCtD
Betaxolol—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000543	0.000575	CcSEcCtD
Betaxolol—Chills—Epirubicin—urinary bladder cancer	0.000541	0.000572	CcSEcCtD
Betaxolol—Pruritus—Etoposide—urinary bladder cancer	0.000541	0.000572	CcSEcCtD
Betaxolol—Arrhythmia—Epirubicin—urinary bladder cancer	0.000538	0.000569	CcSEcCtD
Betaxolol—Visual impairment—Doxorubicin—urinary bladder cancer	0.000537	0.000568	CcSEcCtD
Betaxolol—Alopecia—Epirubicin—urinary bladder cancer	0.000533	0.000563	CcSEcCtD
Betaxolol—Nausea—Gemcitabine—urinary bladder cancer	0.000531	0.000562	CcSEcCtD
Betaxolol—Vomiting—Cisplatin—urinary bladder cancer	0.00053	0.000561	CcSEcCtD
Betaxolol—Vision blurred—Methotrexate—urinary bladder cancer	0.000528	0.000559	CcSEcCtD
Betaxolol—Mental disorder—Epirubicin—urinary bladder cancer	0.000528	0.000558	CcSEcCtD
Betaxolol—Rash—Cisplatin—urinary bladder cancer	0.000526	0.000556	CcSEcCtD
Betaxolol—Dermatitis—Cisplatin—urinary bladder cancer	0.000525	0.000556	CcSEcCtD
Betaxolol—Malnutrition—Epirubicin—urinary bladder cancer	0.000525	0.000555	CcSEcCtD
Betaxolol—Erythema—Epirubicin—urinary bladder cancer	0.000525	0.000555	CcSEcCtD
Betaxolol—Diarrhoea—Etoposide—urinary bladder cancer	0.000523	0.000553	CcSEcCtD
Betaxolol—Nausea—Fluorouracil—urinary bladder cancer	0.000523	0.000553	CcSEcCtD
Betaxolol—Eye disorder—Doxorubicin—urinary bladder cancer	0.000521	0.000551	CcSEcCtD
Betaxolol—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00052	0.00055	CcSEcCtD
Betaxolol—Tinnitus—Doxorubicin—urinary bladder cancer	0.00052	0.00055	CcSEcCtD
Betaxolol—Anaemia—Methotrexate—urinary bladder cancer	0.000518	0.000548	CcSEcCtD
Betaxolol—Flushing—Doxorubicin—urinary bladder cancer	0.000518	0.000547	CcSEcCtD
Betaxolol—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000518	0.000547	CcSEcCtD
Betaxolol—Tension—Epirubicin—urinary bladder cancer	0.000515	0.000545	CcSEcCtD
Betaxolol—Dysgeusia—Epirubicin—urinary bladder cancer	0.000514	0.000543	CcSEcCtD
Betaxolol—Nervousness—Epirubicin—urinary bladder cancer	0.00051	0.000539	CcSEcCtD
Betaxolol—Angiopathy—Doxorubicin—urinary bladder cancer	0.000506	0.000535	CcSEcCtD
Betaxolol—Malaise—Methotrexate—urinary bladder cancer	0.000506	0.000535	CcSEcCtD
Betaxolol—Dizziness—Etoposide—urinary bladder cancer	0.000505	0.000534	CcSEcCtD
Betaxolol—Muscle spasms—Epirubicin—urinary bladder cancer	0.000504	0.000534	CcSEcCtD
Betaxolol—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000504	0.000533	CcSEcCtD
Betaxolol—Vertigo—Methotrexate—urinary bladder cancer	0.000504	0.000533	CcSEcCtD
Betaxolol—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000503	0.000532	CcSEcCtD
Betaxolol—Chills—Doxorubicin—urinary bladder cancer	0.0005	0.000529	CcSEcCtD
Betaxolol—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000498	0.000527	CcSEcCtD
Betaxolol—Nausea—Cisplatin—urinary bladder cancer	0.000495	0.000524	CcSEcCtD
Betaxolol—Vision blurred—Epirubicin—urinary bladder cancer	0.000495	0.000523	CcSEcCtD
Betaxolol—Alopecia—Doxorubicin—urinary bladder cancer	0.000493	0.000521	CcSEcCtD
Betaxolol—Cough—Methotrexate—urinary bladder cancer	0.000489	0.000517	CcSEcCtD
Betaxolol—Mental disorder—Doxorubicin—urinary bladder cancer	0.000489	0.000517	CcSEcCtD
Betaxolol—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000487	0.000515	CcSEcCtD
Betaxolol—Vomiting—Etoposide—urinary bladder cancer	0.000486	0.000514	CcSEcCtD
Betaxolol—Malnutrition—Doxorubicin—urinary bladder cancer	0.000486	0.000513	CcSEcCtD
Betaxolol—Erythema—Doxorubicin—urinary bladder cancer	0.000486	0.000513	CcSEcCtD
Betaxolol—Anaemia—Epirubicin—urinary bladder cancer	0.000485	0.000513	CcSEcCtD
Betaxolol—Rash—Etoposide—urinary bladder cancer	0.000482	0.000509	CcSEcCtD
Betaxolol—Dermatitis—Etoposide—urinary bladder cancer	0.000481	0.000509	CcSEcCtD
Betaxolol—Headache—Etoposide—urinary bladder cancer	0.000479	0.000506	CcSEcCtD
Betaxolol—Arthralgia—Methotrexate—urinary bladder cancer	0.000477	0.000505	CcSEcCtD
Betaxolol—Chest pain—Methotrexate—urinary bladder cancer	0.000477	0.000505	CcSEcCtD
Betaxolol—Myalgia—Methotrexate—urinary bladder cancer	0.000477	0.000505	CcSEcCtD
Betaxolol—Tension—Doxorubicin—urinary bladder cancer	0.000476	0.000504	CcSEcCtD
Betaxolol—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000475	0.000503	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000474	0.000501	CcSEcCtD
Betaxolol—Malaise—Epirubicin—urinary bladder cancer	0.000473	0.0005	CcSEcCtD
Betaxolol—Discomfort—Methotrexate—urinary bladder cancer	0.000472	0.000499	CcSEcCtD
Betaxolol—Nervousness—Doxorubicin—urinary bladder cancer	0.000472	0.000499	CcSEcCtD
Betaxolol—Vertigo—Epirubicin—urinary bladder cancer	0.000471	0.000499	CcSEcCtD
Betaxolol—Syncope—Epirubicin—urinary bladder cancer	0.000471	0.000498	CcSEcCtD
Betaxolol—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000467	0.000494	CcSEcCtD
Betaxolol—Palpitations—Epirubicin—urinary bladder cancer	0.000464	0.00049	CcSEcCtD
Betaxolol—Confusional state—Methotrexate—urinary bladder cancer	0.000461	0.000488	CcSEcCtD
Betaxolol—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000461	0.000488	CcSEcCtD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.000459	0.00843	CbGpPWpGaD
Betaxolol—Cough—Epirubicin—urinary bladder cancer	0.000458	0.000484	CcSEcCtD
Betaxolol—Vision blurred—Doxorubicin—urinary bladder cancer	0.000458	0.000484	CcSEcCtD
Betaxolol—Infection—Methotrexate—urinary bladder cancer	0.000455	0.000481	CcSEcCtD
Betaxolol—CYP2D6—Biological oxidations—GSTZ1—urinary bladder cancer	0.000454	0.00835	CbGpPWpGaD
Betaxolol—Nausea—Etoposide—urinary bladder cancer	0.000454	0.00048	CcSEcCtD
Betaxolol—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.00045	0.000476	CcSEcCtD
Betaxolol—ADRB2—Arf6 trafficking events—CDH1—urinary bladder cancer	0.000449	0.00825	CbGpPWpGaD
Betaxolol—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000449	0.000475	CcSEcCtD
Betaxolol—Anaemia—Doxorubicin—urinary bladder cancer	0.000449	0.000475	CcSEcCtD
Betaxolol—CYP2D6—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000448	0.00823	CbGpPWpGaD
Betaxolol—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000448	0.000474	CcSEcCtD
Betaxolol—Myalgia—Epirubicin—urinary bladder cancer	0.000447	0.000472	CcSEcCtD
Betaxolol—Arthralgia—Epirubicin—urinary bladder cancer	0.000447	0.000472	CcSEcCtD
Betaxolol—Chest pain—Epirubicin—urinary bladder cancer	0.000447	0.000472	CcSEcCtD
Betaxolol—Anxiety—Epirubicin—urinary bladder cancer	0.000445	0.000471	CcSEcCtD
Betaxolol—Skin disorder—Methotrexate—urinary bladder cancer	0.000444	0.00047	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000444	0.000469	CcSEcCtD
Betaxolol—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000442	0.000468	CcSEcCtD
Betaxolol—Discomfort—Epirubicin—urinary bladder cancer	0.000441	0.000467	CcSEcCtD
Betaxolol—Malaise—Doxorubicin—urinary bladder cancer	0.000438	0.000463	CcSEcCtD
Betaxolol—Dry mouth—Epirubicin—urinary bladder cancer	0.000437	0.000462	CcSEcCtD
Betaxolol—Vertigo—Doxorubicin—urinary bladder cancer	0.000436	0.000461	CcSEcCtD
Betaxolol—Anorexia—Methotrexate—urinary bladder cancer	0.000436	0.000461	CcSEcCtD
Betaxolol—Syncope—Doxorubicin—urinary bladder cancer	0.000435	0.00046	CcSEcCtD
Betaxolol—Confusional state—Epirubicin—urinary bladder cancer	0.000432	0.000457	CcSEcCtD
Betaxolol—CYP2D6—Biological oxidations—GSTO2—urinary bladder cancer	0.000431	0.00791	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—NAT1—urinary bladder cancer	0.000431	0.00791	CbGpPWpGaD
Betaxolol—CYP1A2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000429	0.00789	CbGpPWpGaD
Betaxolol—Palpitations—Doxorubicin—urinary bladder cancer	0.000429	0.000454	CcSEcCtD
Betaxolol—Oedema—Epirubicin—urinary bladder cancer	0.000428	0.000453	CcSEcCtD
Betaxolol—Hypotension—Methotrexate—urinary bladder cancer	0.000428	0.000452	CcSEcCtD
Betaxolol—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000427	0.000451	CcSEcCtD
Betaxolol—Infection—Epirubicin—urinary bladder cancer	0.000425	0.00045	CcSEcCtD
Betaxolol—CYP2D6—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000425	0.00781	CbGpPWpGaD
Betaxolol—Cough—Doxorubicin—urinary bladder cancer	0.000424	0.000448	CcSEcCtD
Betaxolol—Shock—Epirubicin—urinary bladder cancer	0.000421	0.000446	CcSEcCtD
Betaxolol—Nervous system disorder—Epirubicin—urinary bladder cancer	0.00042	0.000444	CcSEcCtD
Betaxolol—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000419	0.000443	CcSEcCtD
Betaxolol—Tachycardia—Epirubicin—urinary bladder cancer	0.000418	0.000442	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000417	0.000441	CcSEcCtD
Betaxolol—Skin disorder—Epirubicin—urinary bladder cancer	0.000416	0.00044	CcSEcCtD
Betaxolol—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000414	0.000438	CcSEcCtD
Betaxolol—Insomnia—Methotrexate—urinary bladder cancer	0.000414	0.000438	CcSEcCtD
Betaxolol—Arthralgia—Doxorubicin—urinary bladder cancer	0.000413	0.000437	CcSEcCtD
Betaxolol—Myalgia—Doxorubicin—urinary bladder cancer	0.000413	0.000437	CcSEcCtD
Betaxolol—Chest pain—Doxorubicin—urinary bladder cancer	0.000413	0.000437	CcSEcCtD
Betaxolol—Anxiety—Doxorubicin—urinary bladder cancer	0.000412	0.000436	CcSEcCtD
Betaxolol—Paraesthesia—Methotrexate—urinary bladder cancer	0.000411	0.000435	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00041	0.000434	CcSEcCtD
Betaxolol—Discomfort—Doxorubicin—urinary bladder cancer	0.000408	0.000432	CcSEcCtD
Betaxolol—Anorexia—Epirubicin—urinary bladder cancer	0.000408	0.000432	CcSEcCtD
Betaxolol—Dyspnoea—Methotrexate—urinary bladder cancer	0.000408	0.000431	CcSEcCtD
Betaxolol—Dry mouth—Doxorubicin—urinary bladder cancer	0.000404	0.000428	CcSEcCtD
Betaxolol—Dyspepsia—Methotrexate—urinary bladder cancer	0.000403	0.000426	CcSEcCtD
Betaxolol—Hypotension—Epirubicin—urinary bladder cancer	0.0004	0.000423	CcSEcCtD
Betaxolol—Confusional state—Doxorubicin—urinary bladder cancer	0.0004	0.000423	CcSEcCtD
Betaxolol—Decreased appetite—Methotrexate—urinary bladder cancer	0.000398	0.000421	CcSEcCtD
Betaxolol—Oedema—Doxorubicin—urinary bladder cancer	0.000396	0.000419	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000395	0.000418	CcSEcCtD
Betaxolol—Fatigue—Methotrexate—urinary bladder cancer	0.000395	0.000417	CcSEcCtD
Betaxolol—CYP2D6—Biological oxidations—UGT2B7—urinary bladder cancer	0.000394	0.00724	CbGpPWpGaD
Betaxolol—Infection—Doxorubicin—urinary bladder cancer	0.000394	0.000416	CcSEcCtD
Betaxolol—Pain—Methotrexate—urinary bladder cancer	0.000391	0.000414	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00039	0.000413	CcSEcCtD
Betaxolol—Shock—Doxorubicin—urinary bladder cancer	0.00039	0.000412	CcSEcCtD
Betaxolol—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000389	0.000411	CcSEcCtD
Betaxolol—CYP2D6—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000388	0.00714	CbGpPWpGaD
Betaxolol—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000388	0.00041	CcSEcCtD
Betaxolol—Insomnia—Epirubicin—urinary bladder cancer	0.000387	0.00041	CcSEcCtD
Betaxolol—Tachycardia—Doxorubicin—urinary bladder cancer	0.000387	0.000409	CcSEcCtD
Betaxolol—Skin disorder—Doxorubicin—urinary bladder cancer	0.000385	0.000407	CcSEcCtD
Betaxolol—CYP1A2—Biological oxidations—GSTZ1—urinary bladder cancer	0.000385	0.00707	CbGpPWpGaD
Betaxolol—Paraesthesia—Epirubicin—urinary bladder cancer	0.000385	0.000407	CcSEcCtD
Betaxolol—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000383	0.000405	CcSEcCtD
Betaxolol—Dyspnoea—Epirubicin—urinary bladder cancer	0.000382	0.000404	CcSEcCtD
Betaxolol—CYP1A2—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00038	0.00698	CbGpPWpGaD
Betaxolol—ADRB2—Arf6 signaling events—SRC—urinary bladder cancer	0.000379	0.00697	CbGpPWpGaD
Betaxolol—Anorexia—Doxorubicin—urinary bladder cancer	0.000378	0.000399	CcSEcCtD
Betaxolol—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000377	0.000399	CcSEcCtD
Betaxolol—Dyspepsia—Epirubicin—urinary bladder cancer	0.000377	0.000399	CcSEcCtD
Betaxolol—Decreased appetite—Epirubicin—urinary bladder cancer	0.000372	0.000394	CcSEcCtD
Betaxolol—Hypotension—Doxorubicin—urinary bladder cancer	0.00037	0.000392	CcSEcCtD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.00037	0.0068	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.00037	0.0068	CbGpPWpGaD
Betaxolol—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00037	0.000391	CcSEcCtD
Betaxolol—Fatigue—Epirubicin—urinary bladder cancer	0.000369	0.00039	CcSEcCtD
Betaxolol—Constipation—Epirubicin—urinary bladder cancer	0.000366	0.000387	CcSEcCtD
Betaxolol—Pain—Epirubicin—urinary bladder cancer	0.000366	0.000387	CcSEcCtD
Betaxolol—CYP1A2—Biological oxidations—GSTO2—urinary bladder cancer	0.000365	0.0067	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—NAT1—urinary bladder cancer	0.000365	0.0067	CbGpPWpGaD
Betaxolol—Urticaria—Methotrexate—urinary bladder cancer	0.000364	0.000384	CcSEcCtD
Betaxolol—Body temperature increased—Methotrexate—urinary bladder cancer	0.000362	0.000383	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000361	0.000382	CcSEcCtD
Betaxolol—CYP1A2—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00036	0.00661	CbGpPWpGaD
Betaxolol—Insomnia—Doxorubicin—urinary bladder cancer	0.000358	0.000379	CcSEcCtD
Betaxolol—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000356	0.000376	CcSEcCtD
Betaxolol—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	0.000355	0.00652	CbGpPWpGaD
Betaxolol—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000353	0.000374	CcSEcCtD
Betaxolol—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000353	0.000373	CcSEcCtD
Betaxolol—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00035	0.00643	CbGpPWpGaD
Betaxolol—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000349	0.000369	CcSEcCtD
Betaxolol—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000344	0.000364	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000342	0.000362	CcSEcCtD
Betaxolol—CYP1A2—Phase II conjugation—NAT2—urinary bladder cancer	0.000342	0.00628	CbGpPWpGaD
Betaxolol—Fatigue—Doxorubicin—urinary bladder cancer	0.000342	0.000361	CcSEcCtD
Betaxolol—Urticaria—Epirubicin—urinary bladder cancer	0.00034	0.00036	CcSEcCtD
Betaxolol—Constipation—Doxorubicin—urinary bladder cancer	0.000339	0.000358	CcSEcCtD
Betaxolol—Pain—Doxorubicin—urinary bladder cancer	0.000339	0.000358	CcSEcCtD
Betaxolol—Body temperature increased—Epirubicin—urinary bladder cancer	0.000339	0.000358	CcSEcCtD
Betaxolol—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000337	0.000357	CcSEcCtD
Betaxolol—CYP1A2—Biological oxidations—UGT2B7—urinary bladder cancer	0.000334	0.00613	CbGpPWpGaD
Betaxolol—ADRB2—Arf6 signaling events—EGFR—urinary bladder cancer	0.000332	0.00611	CbGpPWpGaD
Betaxolol—CYP1A2—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000329	0.00605	CbGpPWpGaD
Betaxolol—Asthenia—Methotrexate—urinary bladder cancer	0.000328	0.000347	CcSEcCtD
Betaxolol—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000327	0.000345	CcSEcCtD
Betaxolol—Pruritus—Methotrexate—urinary bladder cancer	0.000324	0.000342	CcSEcCtD
Betaxolol—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000316	0.000334	CcSEcCtD
Betaxolol—Urticaria—Doxorubicin—urinary bladder cancer	0.000315	0.000333	CcSEcCtD
Betaxolol—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000313	0.000331	CcSEcCtD
Betaxolol—Diarrhoea—Methotrexate—urinary bladder cancer	0.000313	0.000331	CcSEcCtD
Betaxolol—Asthenia—Epirubicin—urinary bladder cancer	0.000307	0.000325	CcSEcCtD
Betaxolol—Pruritus—Epirubicin—urinary bladder cancer	0.000303	0.00032	CcSEcCtD
Betaxolol—Dizziness—Methotrexate—urinary bladder cancer	0.000303	0.00032	CcSEcCtD
Betaxolol—CYP1A2—Biological oxidations—CYP4B1—urinary bladder cancer	0.0003	0.00552	CbGpPWpGaD
Betaxolol—CYP1A2—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000296	0.00545	CbGpPWpGaD
Betaxolol—Diarrhoea—Epirubicin—urinary bladder cancer	0.000293	0.00031	CcSEcCtD
Betaxolol—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000292	0.000309	CcSEcCtD
Betaxolol—Vomiting—Methotrexate—urinary bladder cancer	0.000291	0.000308	CcSEcCtD
Betaxolol—Rash—Methotrexate—urinary bladder cancer	0.000289	0.000305	CcSEcCtD
Betaxolol—Dermatitis—Methotrexate—urinary bladder cancer	0.000288	0.000305	CcSEcCtD
Betaxolol—Headache—Methotrexate—urinary bladder cancer	0.000287	0.000303	CcSEcCtD
Betaxolol—Asthenia—Doxorubicin—urinary bladder cancer	0.000284	0.000301	CcSEcCtD
Betaxolol—Dizziness—Epirubicin—urinary bladder cancer	0.000283	0.000299	CcSEcCtD
Betaxolol—Pruritus—Doxorubicin—urinary bladder cancer	0.00028	0.000296	CcSEcCtD
Betaxolol—CYP1A2—Phase II conjugation—HPGDS—urinary bladder cancer	0.000273	0.00502	CbGpPWpGaD
Betaxolol—Vomiting—Epirubicin—urinary bladder cancer	0.000272	0.000288	CcSEcCtD
Betaxolol—Nausea—Methotrexate—urinary bladder cancer	0.000272	0.000287	CcSEcCtD
Betaxolol—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000271	0.000287	CcSEcCtD
Betaxolol—Rash—Epirubicin—urinary bladder cancer	0.00027	0.000286	CcSEcCtD
Betaxolol—Dermatitis—Epirubicin—urinary bladder cancer	0.00027	0.000285	CcSEcCtD
Betaxolol—Headache—Epirubicin—urinary bladder cancer	0.000268	0.000284	CcSEcCtD
Betaxolol—CYP1A2—Phase II conjugation—GSTT1—urinary bladder cancer	0.000265	0.00487	CbGpPWpGaD
Betaxolol—Dizziness—Doxorubicin—urinary bladder cancer	0.000262	0.000277	CcSEcCtD
Betaxolol—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000259	0.00476	CbGpPWpGaD
Betaxolol—Nausea—Epirubicin—urinary bladder cancer	0.000254	0.000269	CcSEcCtD
Betaxolol—CYP1A2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000254	0.00467	CbGpPWpGaD
Betaxolol—Vomiting—Doxorubicin—urinary bladder cancer	0.000252	0.000266	CcSEcCtD
Betaxolol—Rash—Doxorubicin—urinary bladder cancer	0.00025	0.000264	CcSEcCtD
Betaxolol—Dermatitis—Doxorubicin—urinary bladder cancer	0.00025	0.000264	CcSEcCtD
Betaxolol—Headache—Doxorubicin—urinary bladder cancer	0.000248	0.000263	CcSEcCtD
Betaxolol—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.000236	0.00434	CbGpPWpGaD
Betaxolol—Nausea—Doxorubicin—urinary bladder cancer	0.000235	0.000249	CcSEcCtD
Betaxolol—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000233	0.00428	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000223	0.00409	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	0.0002	0.00367	CbGpPWpGaD
Betaxolol—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000197	0.00362	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000194	0.00357	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.000189	0.00347	CbGpPWpGaD
Betaxolol—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	0.000184	0.00337	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.000183	0.00336	CbGpPWpGaD
Betaxolol—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	0.000169	0.0031	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.00016	0.00294	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.00016	0.00294	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	0.000155	0.00285	CbGpPWpGaD
Betaxolol—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.00015	0.00275	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000148	0.00272	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.00014	0.00257	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000133	0.00244	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000133	0.00244	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000129	0.00238	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000129	0.00238	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.000127	0.00233	CbGpPWpGaD
Betaxolol—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000125	0.0023	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.000117	0.00214	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000116	0.00213	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000115	0.00212	CbGpPWpGaD
Betaxolol—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000115	0.00211	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000113	0.00208	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000113	0.00208	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000108	0.00198	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000108	0.00198	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	0.000107	0.00197	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000107	0.00197	CbGpPWpGaD
Betaxolol—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000106	0.00195	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	9.87e-05	0.00181	CbGpPWpGaD
Betaxolol—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	9.74e-05	0.00179	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	9.1e-05	0.00167	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—HDAC4—urinary bladder cancer	9.09e-05	0.00167	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HDAC4—urinary bladder cancer	8.89e-05	0.00163	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	8.06e-05	0.00148	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	7.88e-05	0.00145	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	7.77e-05	0.00143	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—GLI1—urinary bladder cancer	7.62e-05	0.0014	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—GLI1—urinary bladder cancer	7.45e-05	0.00137	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	7.36e-05	0.00135	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NAT1—urinary bladder cancer	7.36e-05	0.00135	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	6.74e-05	0.00124	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	6.58e-05	0.00121	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	6.24e-05	0.00115	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NAT1—urinary bladder cancer	6.24e-05	0.00115	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.14e-05	0.00113	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—CXCL8—urinary bladder cancer	6.14e-05	0.00113	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	6.06e-05	0.00111	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—CXCL8—urinary bladder cancer	6e-05	0.0011	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	5.73e-05	0.00105	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	5.71e-05	0.00105	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	5.58e-05	0.00103	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—RBX1—urinary bladder cancer	5.22e-05	0.000959	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	5.14e-05	0.000944	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—RBX1—urinary bladder cancer	5.11e-05	0.000938	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TSC1—urinary bladder cancer	4.91e-05	0.000902	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	4.85e-05	0.000892	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TSC1—urinary bladder cancer	4.8e-05	0.000882	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	4.73e-05	0.000869	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—JAG1—urinary bladder cancer	4.67e-05	0.000859	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—JAG1—urinary bladder cancer	4.57e-05	0.00084	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—TYMP—urinary bladder cancer	4.46e-05	0.00082	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NAT2—urinary bladder cancer	4.04e-05	0.000742	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—RHOA—urinary bladder cancer	3.95e-05	0.000726	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—RHOA—urinary bladder cancer	3.86e-05	0.00071	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.79e-05	0.000697	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—S100B—urinary bladder cancer	3.78e-05	0.000695	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—TYMP—urinary bladder cancer	3.78e-05	0.000695	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—S100B—urinary bladder cancer	3.7e-05	0.00068	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.63e-05	0.000667	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—RHOA—urinary bladder cancer	3.59e-05	0.000659	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—RHOA—urinary bladder cancer	3.51e-05	0.000645	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—RRM2—urinary bladder cancer	3.48e-05	0.00064	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.47e-05	0.000637	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NAT2—urinary bladder cancer	3.42e-05	0.000628	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—NCOR1—urinary bladder cancer	3.4e-05	0.000625	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.39e-05	0.000623	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NCOR1—urinary bladder cancer	3.33e-05	0.000612	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—IL2—urinary bladder cancer	3.31e-05	0.000609	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—IL2—urinary bladder cancer	3.24e-05	0.000596	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	3.23e-05	0.000593	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ENO2—urinary bladder cancer	3.23e-05	0.000593	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—CXCL8—urinary bladder cancer	3.15e-05	0.000579	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	3.13e-05	0.000575	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—CXCL8—urinary bladder cancer	3.08e-05	0.000566	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—IL2—urinary bladder cancer	3.01e-05	0.000553	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TERT—urinary bladder cancer	3e-05	0.000551	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—RRM2—urinary bladder cancer	2.95e-05	0.000542	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—IL2—urinary bladder cancer	2.94e-05	0.000541	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TERT—urinary bladder cancer	2.93e-05	0.000539	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—FGFR3—urinary bladder cancer	2.75e-05	0.000506	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ENO2—urinary bladder cancer	2.73e-05	0.000502	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	2.73e-05	0.000502	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.72e-05	0.000499	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—FGFR3—urinary bladder cancer	2.69e-05	0.000495	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ESR1—urinary bladder cancer	2.67e-05	0.000491	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	2.65e-05	0.000487	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ESR1—urinary bladder cancer	2.61e-05	0.00048	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.61e-05	0.00048	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NQO1—urinary bladder cancer	2.6e-05	0.000478	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CREBBP—urinary bladder cancer	2.34e-05	0.00043	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—IGF1—urinary bladder cancer	2.31e-05	0.000425	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—EGFR—urinary bladder cancer	2.3e-05	0.000423	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CREBBP—urinary bladder cancer	2.29e-05	0.000421	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—IGF1—urinary bladder cancer	2.26e-05	0.000416	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—EGFR—urinary bladder cancer	2.25e-05	0.000414	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NQO1—urinary bladder cancer	2.2e-05	0.000405	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—KRAS—urinary bladder cancer	2.17e-05	0.0004	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	2.17e-05	0.000399	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.14e-05	0.000393	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—KRAS—urinary bladder cancer	2.13e-05	0.000391	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—RHOA—urinary bladder cancer	2.12e-05	0.000389	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—RHOA—urinary bladder cancer	2.07e-05	0.000381	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—TYMS—urinary bladder cancer	2.02e-05	0.000371	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.99e-05	0.000366	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.99e-05	0.000366	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ERBB2—urinary bladder cancer	1.96e-05	0.00036	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ERBB2—urinary bladder cancer	1.92e-05	0.000353	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.91e-05	0.000351	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.87e-05	0.000344	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.86e-05	0.000343	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CXCL8—urinary bladder cancer	1.86e-05	0.000342	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—HRAS—urinary bladder cancer	1.85e-05	0.00034	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.84e-05	0.000338	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CXCL8—urinary bladder cancer	1.82e-05	0.000334	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—HRAS—urinary bladder cancer	1.81e-05	0.000332	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.78e-05	0.000327	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—IL2—urinary bladder cancer	1.78e-05	0.000327	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.76e-05	0.000324	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—IL2—urinary bladder cancer	1.74e-05	0.00032	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CCND1—urinary bladder cancer	1.73e-05	0.000318	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.71e-05	0.000314	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CCND1—urinary bladder cancer	1.7e-05	0.000312	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.69e-05	0.00031	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.69e-05	0.00031	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MMP9—urinary bladder cancer	1.68e-05	0.000309	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.68e-05	0.000308	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PTEN—urinary bladder cancer	1.67e-05	0.000307	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MMP9—urinary bladder cancer	1.65e-05	0.000302	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.64e-05	0.000301	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PTEN—urinary bladder cancer	1.64e-05	0.000301	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.62e-05	0.000297	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—EP300—urinary bladder cancer	1.6e-05	0.000293	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.59e-05	0.000292	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—EP300—urinary bladder cancer	1.56e-05	0.000287	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—SRC—urinary bladder cancer	1.55e-05	0.000285	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—SRC—urinary bladder cancer	1.52e-05	0.000279	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.49e-05	0.000274	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.43e-05	0.000262	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MYC—urinary bladder cancer	1.39e-05	0.000255	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.37e-05	0.000252	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MYC—urinary bladder cancer	1.36e-05	0.00025	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—EGFR—urinary bladder cancer	1.36e-05	0.00025	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—EGFR—urinary bladder cancer	1.33e-05	0.000244	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—KRAS—urinary bladder cancer	1.28e-05	0.000236	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—KRAS—urinary bladder cancer	1.26e-05	0.000231	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.21e-05	0.000222	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.16e-05	0.000214	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TP53—urinary bladder cancer	1.14e-05	0.00021	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.12e-05	0.000206	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TP53—urinary bladder cancer	1.12e-05	0.000205	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—HRAS—urinary bladder cancer	1.09e-05	0.000201	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HRAS—urinary bladder cancer	1.07e-05	0.000196	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PTEN—urinary bladder cancer	9.8e-06	0.00018	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	9.52e-06	0.000175	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—EP300—urinary bladder cancer	9.34e-06	0.000172	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PTEN—urinary bladder cancer	8.3e-06	0.000153	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—EP300—urinary bladder cancer	7.92e-06	0.000145	CbGpPWpGaD
